Genmab Announces Net Sales of DARZALEX® (daratumumab) for First Quarter of 2026
14/4 12:23
Company Announcement Net sales of DARZALEX ® in the first quarter of 2026 totaled USD 3,964 million Genmab receives royalties on worldwide net sales from Johnson & Johnson (J&J, legal entity Janssen Biotech, Inc.) COPENHAGEN, Denmark; April 14, 2026 – Genmab A/S (Nasdaq: GMAB) announced today that...